Sex and gender equity in health - Our position
Delve into why we are considering the influence of sex and gender on health and medical research with our key policy reads and perspectives.
Australia has new health research gender standards – and centuries of inequity to fixLearn more
Integrating sex and gender into biomedical research requires policy and culture changeLearn more
Women’s Health: A New Global Agenda Policy PaperLearn more
A roadmap for sex- and gender-disaggregated health researchLearn more
Women’s health needs beyond sexual, reproductive, and maternal health are missing OpinionLearn more
Closing the Gender Health Gap: A Call for Sex and Gender Equity in Biomedical Research PoliciesLearn more
Our team
VERONICA: deliVERy of Optimal blood pressure coNtrol in afrICA
Background
High blood pressure (BP) is the leading cause of preventable morbidity and mortality globally. The benefits of BP lowering in reducing cardiovascular (CV) events are well established and there is clear evidence that greater BP lowering confers a greater reduction in CV events. However, control of high BP is poor globally, with only one in three treated patients achieving traditional BP goals. Most treated patients receive only monotherapy, despite guidelines recognising that most patients require multiple medications to achieve target BP.
Over the recent decades, the burden of non-communicable diseases (NCD)s in Sub-Saharan Africa (SSA) has rapidly increased and high BP is the leading cause and increase continues, the burden of NCDs will soon surpass that of “traditional” communicable, maternal, neonatal and nutritional diseases. Nigeria, with a population of 207 million, is anticipated to become the 3rd most populous country in 2050. This portends a huge increase in the number
Comparison of removable off-loading device and routine care to heal plantar ulcers due to leprosy and diabetes in the community
Background
Plantar ulcers are a serious complication in leprosy and diabetes globally resulting in hospitalization, disability, and amputation. Continued pressure over the vulnerable site leads to ulcers and then impedes ulcer healing. Therefore, in addition to removal of infection off-loading the ulcer area is essential to heal the ulcer. The current proposed feasibility plus study is based on removable off-loading walker boot fitted with soft insole which can be easily applied with limited training and may allow the patient to continue their essential daily routine activities. We will test the feasibility and acceptability of using this device and set the scene for a potential trial to test the effectiveness of this device type in reducing ulcer development and ulcer complications in community setting.
Aim
To compare a removable pressure-relieving off-loading device with standard routine care for healing plantar ulcers due to leprosy and diabetes in the community.
Design
Clinical and community trial
We work with civil society groups and networks at local, regional and global levels, sharing evidence and identifying opportunities to influence health-related decisions. Our collective advocacy aims to build momentum and drive changes that reduce inequities and improve the health of millions of people worldwide.We work with civil society groups and networks at local, regional and global levels, sharing evidence and identifying opportunities to influence health-related decisions. Our collective advocacy aims to build momentum and drive changes that reduce inequities and improve the health of millions of people worldwide.We work with civil society groups and networks at local, regional and global levels, sharing evidence and identifying opportunities to influence health-related decisions. Our collective advocacy aims to build momentum and drive changes that reduce inequities and improve the health of millions of people worldwide.
About this study
Intergenerational programs that bring pre-school
this is another page 2
j,mhjkhj hjhjhhjhjhjhjm hjhjm
Child page 1
Child page 1
Child page 2
Child page 2
Clinical and community trials
About this study
Intracerebral haemorrhage (ICH), bleeding into the brain, is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur in the world each year.
Patients fortunate enough to survive an ICH are at very high risk of another ICH as well as heart attacks and other serious heart-related events. Whilst there is strong evidence that these risks can be reduced by good control of blood pressure (BP), many patients do not receive any BP lowering treatment or that this treatment is inadequate.
TRIDENT aims to determine the benefits of using three different BP medications (each at half the normal dose) in a single pill on preventing another stroke. This capsule with the three medications, is called the Triple Pill. The study is hoping to enrol and treat 1500 people.
Recruitment criteria
Inclusion criteria
Adults with a history of ICH stroke
Average resting BP in the 130-160 mmHg range
Clinical and community trials
About this study
People with advanced kidney disease or those receiving dialysis often have other diseases related to the heart, brain and blood vessels, known as vascular disease (for example, heart attack, stroke and poor blood circulation). However, few treatments have been proven to prevent these conditions in people with advanced kidney disease. Blood thinners (medicines that prevent blood clots) are frequently used and proven to help other groups of people who are at high risk of vascular disease.
There is little understanding of whether blood thinners provide similar benefits in people with advanced kidney disease. The aim of the TRACK study is to find out whether a low dose of blood thinning medicine can reduce heart and vascular disease better than placebo (a look alike tablet that contains no active medication) in people with advanced kidney disease.
Recruitment criteria
Inclusion:
Age ≥18 years,
Advanced kidney disease (kidney failure on dialysis, or
Community Action for Safe Speeds (CASS) Study
Background
Speeding remains a major contributing factor in road crashes and associated road trauma. Non-compliance with posted speed limits is a widespread international problem and survey research consistently demonstrates widespread misperceptions about the risks of speeding and negative community attitudes towards speed management initiatives. Having positive public attitudes towards safe travel speeds is critical to speed limit compliance, as is public understanding of the risks associated with unsafe speeds. A widespread challenge relates to how to shift the community’s attitudes on speeding and increase their acceptance of speed management interventions which in turn would increase public demand for safer speeds. These sentiments are reflected in a 2016 Austroads report titled “Public Demand for Safer Speeds: Identification of Interventions for Trial” and are acknowledged by the Australian National Road Safety Strategy as it pushes for a wholistic approach to Speed Management.
Trad
ACT-GLOBAL: A multi-faCtorial, mulTi-arm, multi-staGe, randomised, gLOBal Adaptive pLatform trial for stroke
Background
Stroke remains a leading cause of death and disability worldwide. Despite advances in medical technology and treatment strategies, many patients still do not achieve optimal outcomes. The George Institute’s ACT-GLOBAL study is an adaptive platform trial that is aiming to address the urgent need for the development of new and more effective interventions for stroke patients across the world.
A platform trial involves study of several different clinical questions at the same time, essentially uniting multiple clinical trials or ‘Domains’ under a single organisational structure lead by experts in the field. Adaptive design allows the team to add or collapse (if needed) research questions during the trial as more information is collected. We believe the adaptive platform approach is a uniquely flexible and efficient way to conduct ground-breaking research.
The ACT-GLOBAL platform currently has several domains across the stroke-subtypes of Acute Ischemic Stroke, where a bloc
